Login Register Cart 0
Review Article

基因表达检测在早期乳腺癌治疗中的作用

卷 27, 期 17, 2020

页: [2826 - 2839] 页: 14

弟呕挨: 10.2174/0929867326666191205163329

价格: $65

Open Access Journals Promotions 2
conference banner
摘要

在雌激素受体阳性的早期乳腺癌患者中，在激素治疗之外加用辅助化疗通常被认为是有问题的。单纯内分泌治疗后的低复发风险和/或对化疗的低敏感性是并不是所有患者都能从化疗中受益的原因。当治疗决策仅仅基于典型的临床组织学特征时，大多数患者可能暴露于不必要的治疗相关不良事件和医疗费用。基因表达谱已被开发，以完善医生的决策过程和定制个性化治疗的患者。特别是，这些检查的设计是为了避免患者不必要治疗的副作用，并确保辅助化疗被正确推荐给早期乳腺癌患者。在这篇综述中，我们将讨论主要的诊断试验及其潜在的临床应用【Oncotype DX（安可待）, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant DX, IHC4，和Theros-Breast Cancer基因表达比测定)。

关键词: 辅助化疗，早期乳腺癌(EBC)， Oncotype DX

« Previous Next »
[1]
Coates, A.S.; Winer, E.P.; Goldhirsch, A.; Gelber, R.D.; Gnant, M.; Piccart-Gebhart, M.; Thürlimann, B.; Senn, H.J. Panel members. Tailoring therapies--improving the management of early breast cancer: St. Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann. Oncol., 2015, 26(8), 1533-1546.
[http://dx.doi.org/10.1093/annonc/mdv221] [PMID: 25939896]
[2]
Loprinzi, C.L.; Ravdin, P.M.; de Laurentiis, M.; Novotny, P. Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? J. Clin. Oncol., 1994, 12(7), 1422-1426.
[http://dx.doi.org/10.1200/JCO.1994.12.7.1422] [PMID: 8021733]
[3]
Marchionni, L.; Wilson, R.F.; Marinopoulos, S.S.; Wolff, A.C.; Parmigiani, G.; Bass, E.B.; Goodman, S.N. Impact of gene expression profiling tests on breast cancer outcomes. Evid. Rep. Technol. Assess. (Full. Rep), 2007, (160), 1-105.
[PMID: 18457476]
[4]
Harris, L.N.; Ismaila, N.; McShane, L.M.; Andre, F.; Collyar, D.E.; Gonzalez-Angulo, A.M.; Hammond, E.H.; Kuderer, N.M.; Liu, M.C.; Mennel, R.G.; Van Poznak, C.; Bast, R.C.; Hayes, D.F. American Society of Clinical Oncology. American society of clinical oncology. use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: american society of clinical oncology clinical practice guideline. J. Clin. Oncol., 2016, 34(10), 1134-1150.
[http://dx.doi.org/10.1200/JCO.2015.65.2289] [PMID: 26858339]
[5]
Cronin, M.; Sangli, C.; Liu, M.L.; Pho, M.; Dutta, D.; Nguyen, A.; Jeong, J.; Wu, J.; Langone, K.C.; Watson, D. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem., 2007, 53(6), 1084-1091.
[http://dx.doi.org/10.1373/clinchem.2006.076497] [PMID: 17463177]
[6]
Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F.L.; Walker, M.G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E.R.; Wickerham, D.L.; Bryant, J.; Wolmark, N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med., 2004, 351(27), 2817-2826.
[http://dx.doi.org/10.1056/NEJMoa041588] [PMID: 15591335]
[7]
Paik, S.; Tang, G.; Shak, S.; Kim, C.; Baker, J.; Kim, W.; Cronin, M.; Baehner, F.L.; Watson, D.; Bryant, J.; Costantino, J.P.; Geyer, C.E., Jr; Wickerham, D.L.; Wolmark, N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol., 2006, 24(23), 3726-3734.
[http://dx.doi.org/10.1200/JCO.2005.04.7985] [PMID: 16720680]
[8]
Habel, L.A.; Shak, S.; Jacobs, M.K.; Capra, A.; Alexander, C.; Pho, M.; Baker, J.; Walker, M.; Watson, D.; Hackett, J.; Blick, N.T.; Greenberg, D.; Fehrenbacher, L.; Langholz, B.; Quesenberry, C.P. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res., 2006, 8(3), R25.
[http://dx.doi.org/10.1186/bcr1412] [PMID: 16737553]
[9]
Goldstein, L.J.; Gray, R.; Badve, S.; Childs, B.H.; Yoshizawa, C.; Rowley, S.; Shak, S.; Baehner, F.L.; Ravdin, P.M.; Davidson, N.E.; Sledge, G.W., Jr; Perez, E.A.; Shulman, L.N.; Martino, S.; Sparano, J.A. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol., 2008, 26(25), 4063-4071.
[http://dx.doi.org/10.1200/JCO.2007.14.4501] [PMID: 18678838]
[10]
Albain, K.S.; Barlow, W.E.; Shak, S.; Hortobagyi, G.N.; Livingston, R.B.; Yeh, I.T.; Ravdin, P.; Bugarini, R.; Baehner, F.L.; Davidson, N.E.; Sledge, G.W.; Winer, E.P.; Hudis, C.; Ingle, J.N.; Perez, E.A.; Pritchard, K.I.; Shepherd, L.; Gralow, J.R.; Yoshizawa, C.; Allred, D.C.; Osborne, C.K.; Hayes, D.F. Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol., 2010, 11(1), 55-65.
[http://dx.doi.org/10.1016/S1470-2045(09)70314-6] [PMID: 20005174]
[11]
Dowsett, M.; Cuzick, J.; Wale, C.; Forbes, J.; Mallon, E.A.; Salter, J.; Quinn, E.; Dunbier, A.; Baum, M.; Buzdar, A.; Howell, A.; Bugarini, R.; Baehner, F.L.; Shak, S. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol., 2010, 28(11), 1829-1834.
[http://dx.doi.org/10.1200/JCO.2009.24.4798] [PMID: 20212256]
[12]
Toi, M.; Iwata, H.; Yamanaka, T.; Masuda, N.; Ohno, S.; Nakamura, S.; Nakayama, T.; Kashiwaba, M.; Kamigaki, S.; Kuroi, K. Japan Breast Cancer Research Group-Translational Research Group. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer, 2010, 116(13), 3112-3118.
[http://dx.doi.org/10.1002/cncr.25206] [PMID: 20564629]
[13]
Mamounas, E.P.; Tang, G.; Paik, S.; Baehner, F.L.; Liu, Q.; Jeong, J.H.; Kim, S.R.; Butler, S.M.; Jamshidian, F.; Cherbavaz, D.B.; Sing, A.P.; Shak, S.; Julian, T.B.; Lembersky, B.C.; Wickerham, D.L.; Costantino, J.P.; Wolmark, N. Association between the 21-gene Recurrence Score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (Nþ), ER-positive breast cancer patients (pts): results from NSABP B-28. Cancer Res, 2012, 72(Supp. 24), S1-10-S1- 10.
[http://dx.doi.org/10.1158/0008-5472.SABCS12-S1-10]
[14]
Simon, R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol., 2005, 23(29), 7332-7341.
[http://dx.doi.org/10.1200/JCO.2005.02.8712] [PMID: 16145063]
[15]
Simon, R.M.; Paik, S.; Hayes, D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst., 2009, 101(21), 1446-1452.
[http://dx.doi.org/10.1093/jnci/djp335] [PMID: 19815849]
[16]
Sparano, J.A. TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer, 2006, 7(4), 347-350.
[http://dx.doi.org/10.3816/CBC.2006.n.051] [PMID: 17092406]
[17]
Sparano, J.A.; Gray, R.J.; Makower, D.F.; Pritchard, K.I.; Albain, K.S.; Hayes, D.F.; Geyer, C.E., Jr; Dees, E.C.; Perez, E.A.; Olson, J.A., Jr; Zujewski, J.; Lively, T.; Badve, S.S.; Saphner, T.J.; Wagner, L.I.; Whelan, T.J.; Ellis, M.J.; Paik, S.; Wood, W.C.; Ravdin, P.; Keane, M.M.; Gomez Moreno, H.L.; Reddy, P.S.; Goggins, T.F.; Mayer, I.A.; Brufsky, A.M.; Toppmeyer, D.L.; Kaklamani, V.G.; Atkins, J.N.; Berenberg, J.L.; Sledge, G.W. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N. Engl. J. Med., 2015, 373(21), 2005-2014.
[http://dx.doi.org/10.1056/NEJMoa1510764] [PMID: 26412349]
[18]
Gonzalez-Angulo, A.M.; Barlow, W.E.; Gralow, J.R.; Meric-Bernstam, F.; Hayes, D.F.; Moinpour, C.M.; Ramsey, S.D.; Schott, A.F.; Sparks, D.B.; Albain, K.S.; Hortobagyi, G.N. OT1-03-01: A randomized phase III clinical trial of standard adjuvant en-docrine therapy +/- chemotherapy in patients (pts) with 1-3 positive nodes, hormone receptor (HR)-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less: SWOG S1007. Cancer Res., 2011, 71(Suppl. 24) OT1-03-01-OT1-03-01.
[http://dx.doi.org/10.1158/0008-5472.SABCS11-OT1-03-01]
[19]
Mook, S.; Schmidt, M.K.; Viale, G.; Pruneri, G.; Eekhout, I.; Floore, A.; Glas, A.M.; Bogaerts, J.; Cardoso, F.; Piccart-Gebhart, M.J.; Rutgers, E.T.; Van’t Veer, L.J. TRANSBIG Consortium. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat., 2009, 116(2), 295-302.
[http://dx.doi.org/10.1007/s10549-008-0130-2] [PMID: 18661261]
[20]
Mittempergher, L.; de Ronde, J.J.; Nieuwland, M.; Kerkhoven, R.M.; Simon, I.; Rutgers, E.J.; Wessels, L.F.; Van’t Veer, L.J. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One, 2011, 6(2) e17163
[http://dx.doi.org/10.1371/journal.pone.0017163] [PMID: 21347257]
[21]
van ’t Veer, L.J.; Dai, H.; van de Vijver, M.J.; He, Y.D.; Hart, A.A.; Mao, M.; Peterse, H.L.; van der Kooy, K.; Marton, M.J.; Witteveen, A.T.; Schreiber, G.J.; Kerkhoven, R.M.; Roberts, C.; Linsley, P.S.; Bernards, R.; Friend, S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415(6871), 530-536.
[http://dx.doi.org/10.1038/415530a] [PMID: 11823860]
[22]
van de Vijver, M.J.; He, Y.D.; van’t Veer, L.J.; Dai, H.; Hart, A.A.; Voskuil, D.W.; Schreiber, G.J.; Peterse, J.L.; Roberts, C.; Marton, M.J.; Parrish, M.; Atsma, D.; Witteveen, A.; Glas, A.; Delahaye, L.; van der Velde, T.; Bartelink, H.; Rodenhuis, S.; Rutgers, E.T.; Friend, S.H.; Bernards, R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 2002, 347(25), 1999-2009.
[http://dx.doi.org/10.1056/NEJMoa021967] [PMID: 12490681]
[23]
Buyse, M.; Loi, S.; van’t Veer, L.; Viale, G.; Delorenzi, M.; Glas, A.M.; d’Assignies, M.S.; Bergh, J.; Lidereau, R.; Ellis, P.; Harris, A.; Bogaerts, J.; Therasse, P.; Floore, A.; Amakrane, M.; Piette, F.; Rutgers, E.; Sotiriou, C.; Cardoso, F.; Piccart, M.J. TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst., 2006, 98(17), 1183-1192.
[http://dx.doi.org/10.1093/jnci/djj329] [PMID: 16954471]
[24]
Goldhirsch, A.; Winer, E.P.; Coates, A.S.; Gelber, R.D.; Piccart-Gebhart, M.; Thürlimann, B.; Senn, H.J. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol., 2013, 24(9), 2206-2223.
[http://dx.doi.org/10.1093/annonc/mdt303] [PMID: 23917950]
[25]
Bueno-de-Mesquita, J.M.; Sonke, G.S.; van de Vijver, M.J.; Linn, S.C. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Ann. Oncol., 2011, 22(9), 2021-2030.
[http://dx.doi.org/10.1093/annonc/mdp547] [PMID: 19955335]
[26]
Wittner, B.S.; Sgroi, D.C.; Ryan, P.D.; Bruinsma, T.J.; Glas, A.M.; Male, A.; Dahiya, S.; Habin, K.; Bernards, R.; Haber, D.A.; Van’t Veer, L.J.; Ramaswamy, S. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin. Cancer Res., 2008, 14(10), 2988-2993.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-4723] [PMID: 18483364]
[27]
Mook, S.; Schmidt, M.K.; Weigelt, B.; Kreike, B.; Eekhout, I.; van de Vijver, M.J.; Glas, A.M.; Floore, A.; Rutgers, E.J.; van ’t Veer, L.J. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann. Oncol., 2010, 21(4), 717-722.
[http://dx.doi.org/10.1093/annonc/mdp388] [PMID: 19825882]
[28]
Drukker, C.A.; Bueno-de-Mesquita, J.M.; Retèl, V.P.; van Harten, W.H.; van Tinteren, H.; Wesseling, J.; Roumen, R.M.; Knauer, M.; van ’t Veer, L.J.; Sonke, G.S.; Rutgers, E.J.; van de Vijver, M.J.; Linn, S.C. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int. J. Cancer, 2013, 133(4), 929-936.
[http://dx.doi.org/10.1002/ijc.28082] [PMID: 23371464]
[29]
Cardoso, F.; van’t Veer, L.J.; Bogaerts, J.; Slaets, L.; Viale, G.; Delaloge, S.; Pierga, J.Y.; Brain, E.; Causeret, S.; DeLorenzi, M.; Glas, A.M.; Golfinopoulos, V.; Goulioti, T.; Knox, S.; Matos, E.; Meulemans, B.; Neijenhuis, P.A.; Nitz, U.; Passalacqua, R.; Ravdin, P.; Rubio, I.T.; Saghatchian, M.; Smilde, T.J.; Sotiriou, C.; Stork, L.; Straehle, C.; Thomas, G.; Thompson, A.M.; van der Hoeven, J.M.; Vuylsteke, P.; Bernards, R.; Tryfonidis, K.; Rutgers, E.; Piccart, M. MINDACT Investigators. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med., 2016, 375(8), 717-729.
[http://dx.doi.org/10.1056/NEJMoa1602253] [PMID: 27557300]
[30]
Perou, C.M.; Sørlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S.X.; Lønning, P.E.; Børresen-Dale, A.L.; Brown, P.O.; Botstein, D. Molecular portraits of human breast tumours. Nature, 2000, 406(6797), 747-752.
[http://dx.doi.org/10.1038/35021093] [PMID: 10963602]
[31]
Sørlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Thorsen, T.; Quist, H.; Matese, J.C.; Brown, P.O.; Botstein, D.; Lønning, P.E.; Børresen-Dale, A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA, 2001, 98(19), 10869-10874.
[http://dx.doi.org/10.1073/pnas.191367098] [PMID: 11553815]
[32]
Parker, J.S.; Mullins, M.; Cheang, M.C.; Leung, S.; Voduc, D.; Vickery, T.; Davies, S.; Fauron, C.; He, X.; Hu, Z.; Quackenbush, J.F.; Stijleman, I.J.; Palazzo, J.; Marron, J.S.; Nobel, A.B.; Mardis, E.; Nielsen, T.O.; Ellis, M.J.; Perou, C.M.; Bernard, P.S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol., 2009, 27(8), 1160-1167.
[http://dx.doi.org/10.1200/JCO.2008.18.1370] [PMID: 19204204]
[33]
Reis, P.P.; Waldron, L.; Goswami, R.S.; Xu, W.; Xuan, Y.; Perez-Ordonez, B.; Gullane, P.; Irish, J.; Jurisica, I.; Kamel-Reid, S. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol., 2011, 11, 46.
[http://dx.doi.org/10.1186/1472-6750-11-46] [PMID: 21549012]
[34]
Nielsen, T.O.; Parker, J.S.; Leung, S.; Voduc, D.; Ebbert, M.; Vickery, T.; Davies, S.R.; Snider, J.; Stijleman, I.J.; Reed, J.; Cheang, M.C.; Mardis, E.R.; Perou, C.M.; Bernard, P.S.; Ellis, M.J. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res., 2010, 16(21), 5222-5232.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-1282] [PMID: 20837693]
[35]
Wallden, B.; Storhoff, J.; Nielsen, T.; Dowidar, N.; Schaper, C.; Ferree, S.; Liu, S.; Leung, S.; Geiss, G.; Snider, J.; Vickery, T.; Davies, S.R.; Mardis, E.R.; Gnant, M.; Sestak, I.; Ellis, M.J.; Perou, C.M.; Bernard, P.S.; Parker, J.S. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med. Genomics, 2015, 8, 54.
[http://dx.doi.org/10.1186/s12920-015-0129-6] [PMID: 26297356]
[36]
Gnant, M.; Filipits, M.; Greil, R.; Stoeger, H.; Rudas, M.; Bago-Horvath, Z.; Mlineritsch, B.; Kwasny, W.; Knauer, M.; Singer, C.; Jakesz, R.; Dubsky, P.; Fitzal, F.; Bartsch, R.; Steger, G.; Balic, M.; Ressler, S.; Cowens, J.W.; Storhoff, J.; Ferree, S.; Schaper, C.; Liu, S.; Fesl, C.; Nielsen, T.O. Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann. Oncol., 2014, 25(2), 339-345.
[http://dx.doi.org/10.1093/annonc/mdt494] [PMID: 24347518]
[37]
Chia, S.K.; Bramwell, V.H.; Tu, D.; Shepherd, L.E.; Jiang, S.; Vickery, T.; Mardis, E.; Leung, S.; Ung, K.; Pritchard, K.I.; Parker, J.S.; Bernard, P.S.; Perou, C.M.; Ellis, M.J.; Nielsen, T.O. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin. Cancer Res., 2012, 18(16), 4465-4472.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-0286] [PMID: 22711706]
[38]
Prat, A.; Bianchini, G.; Thomas, M.; Belousov, A.; Cheang, M.C.; Koehler, A.; Gómez, P.; Semiglazov, V.; Eiermann, W.; Tjulandin, S.; Byakhow, M.; Bermejo, B.; Zambetti, M.; Vazquez, F.; Gianni, L.; Baselga, J. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin. Cancer Res., 2014, 20(2), 511-521.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-0239] [PMID: 24443618]
[39]
Martin, M.; Romero, A.; Cheang, M.C.; López García-Asenjo, J.A.; García-Saenz, J.A.; Oliva, B.; Román, J.M.; He, X.; Casado, A.; de la Torre, J.; Furio, V.; Puente, J.; Caldés, T.; Vidart, J.A.; Lopez-Tarruella, S.; Diaz-Rubio, E.; Perou, C.M. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res. Treat., 2011, 128(1), 127-136.
[http://dx.doi.org/10.1007/s10549-011-1461-y] [PMID: 21465170]
[40]
Harvell, D.M.; Spoelstra, N.S.; Singh, M.; McManaman, J.L.; Finlayson, C.; Phang, T.; Trapp, S.; Hunter, L.; Dye, W.W.; Borges, V.F.; Elias, A.; Horwitz, K.B.; Richer, J.K. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res. Treat., 2008, 112(3), 475-488.
[http://dx.doi.org/10.1007/s10549-008-9897-4] [PMID: 18327671]
[41]
Cheang, M.C.; Voduc, K.D.; Tu, D.; Jiang, S.; Leung, S.; Chia, S.K.; Shepherd, L.E.; Levine, M.N.; Pritchard, K.I.; Davies, S.; Stijleman, I.J.; Davis, C.; Ebbert, M.T.; Parker, J.S.; Ellis, M.J.; Bernard, P.S.; Perou, C.M.; Nielsen, T.O. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin. Cancer Res., 2012, 18, 2402-2412.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-2956] [PMID: 22351696]
[42]
Esserman, L.J.; Berry, D.A.; Cheang, M.C.; Yau, C.; Perou, C.M.; Carey, L.; DeMichele, A.; Gray, J.W.; Conway-Dorsey, K.; Lenburg, M.E.; Buxton, M.B.; Davis, S.E.; van’t Veer, L.J.; Hudis, C.; Chin, K.; Wolf, D.; Krontiras, H.; Montgomery, L.; Tripathy, D.; Lehman, C.; Liu, M.C.; Olopade, O.I.; Rugo, H.S.; Carpenter, J.T.; Livasy, C.; Dressler, L.; Chhieng, D.; Singh, B.; Mies, C.; Rabban, J.; Chen, Y.Y.; Giri, D.; Au, A.; Hylton, N. I-SPY 1 TRIAL Investigators. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res. Treat., 2012, 132(3), 1049-1062.
[http://dx.doi.org/10.1007/s10549-011-1895-2] [PMID: 22198468]
[43]
Martín, M.; Prat, A.; Rodríguez-Lescure, A.; Caballero, R.; Ebbert, M.T.; Munárriz, B.; Ruiz-Borrego, M.; Bastien, R.R.; Crespo, C.; Davis, C.; Rodríguez, C.A.; López-Vega, J.M.; Furió, V.; García, A.M.; Casas, M.; Ellis, M.J.; Berry, D.A.; Pitcher, B.N.; Harris, L.; Ruiz, A.; Winer, E.; Hudis, C.; Stijleman, I.J.; Tuck, D.P.; Carrasco, E.; Perou, C.M.; Bernard, P.S. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res. Treat., 2013, 138(2), 457-466.
[http://dx.doi.org/10.1007/s10549-013-2416-2] [PMID: 23423445]
[44]
Liu, M.C.; Pitcher, B.N.; Mardis, E.R.; Davies, S.R.; Friedman, P.N.; Snider, J.E.; Vickery, T.L.; Reed, J.P.; DeSchryver, K.; Singh, B.; Gradishar, W.J.; Perez, E.A.; Martino, S.; Citron, M.L.; Norton, L.; Winer, E.P.; Hudis, C.A.; Carey, L.A.; Bernard, P.S.; Nielsen, T.O.; Perou, C.M.; Ellis, M.J.; Barry, W.T. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer, 2016, 2, 15023.
[http://dx.doi.org/10.1038/npjbcancer.2015.23] [PMID: 28691057]
[45]
Dowsett, M.; Sestak, I.; Lopez-Knowles, E.; Sidhu, K.; Dunbier, A.K.; Cowens, J.W.; Ferree, S.; Storhoff, J.; Schaper, C.; Cuzick, J. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J. Clin. Oncol., 2013, 31(22), 2783-2790.
[http://dx.doi.org/10.1200/JCO.2012.46.1558] [PMID: 23816962]
[46]
Sestak, I.; Dowsett, M.; Zabaglo, L.; Lopez-Knowles, E.; Ferree, S.; Cowens, J.W.; Cuzick, J. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J. Natl. Cancer Inst., 2013, 105(19), 1504-1511.
[http://dx.doi.org/10.1093/jnci/djt244] [PMID: 24029245]
[47]
Gnant, M.; Filipits, M.; Mlineritsch, B.; Dubsky, P.; Jakesz, R.; Kwasny, W.; Fitzal, F.; Rudas, M.; Knauer, M.; Singer, C.; Greil, R.; Ferree, S.; Storhoff, J.; Cowens, J.W.; Schaper, C.; Liu, S.; Nielsen, T. Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER + early breast cancer (EBC): An ABCSG study. Cancer Res., 2012, 72(Suppl. 24) P2-10-02.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-1845] [PMID: 24520097]
[48]
Gnant, M.; Filipits, M.; Dubsky, P.; Rudas, M.; Balic, M.; Greil, R.; Ferree, S.; Cowens, J.W.; Schaper, C.; Nielsen, T. Predicting risk for late metastasis: The PAM50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR + early breast cancer: A study on 1,478 patients from the ABCSG-8 trial. Ann. Oncol., 2013, 24(3), 29.
[http://dx.doi.org/10.1093/annonc/mdt084.1]
[49]
Gnant, M.; Sestak, I.; Filipits, M.; Dowsett, M.; Balic, M.; Lopez-Knowles, E.; Greil, R.; Dubsky, P.; Stoeger, H.; Rudas, M.; Jakesz, R.; Ferree, S.; Cowens, J.W.; Nielsen, T.; Schaper, C.; Fesl, C.; Cuzick, J. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann. Oncol., 2015, 26(8), 1685-1691.
[http://dx.doi.org/10.1093/annonc/mdv215] [PMID: 25935792]
[50]
Sestak, I.; Cuzick, J.; Dowsett, M.; Lopez-Knowles, E.; Filipits, M.; Dubsky, P.; Cowens, J.W.; Ferree, S.; Schaper, C.; Fesl, C.; Gnant, M. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J. Natl. Cancer Inst., 2013, 105, 1504-1511.
[http://dx.doi.org/10.1093/jnci/djt244] [PMID: 24029245]
[51]
Prat, A.; Parker, J.S.; Fan, C.; Cheang, M.C.; Miller, L.D.; Bergh, J.; Chia, S.K.; Bernard, P.S.; Nielsen, T.O.; Ellis, M.J.; Carey, L.A.; Perou, C.M. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann. Oncol., 2012, 23(11), 2866-2873.
[http://dx.doi.org/10.1093/annonc/mds080] [PMID: 22532584]
[52]
Filipits, M.; Rudas, M.; Jakesz, R.; Dubsky, P.; Fitzal, F.; Singer, C.F.; Dietze, O.; Greil, R.; Jelen, A.; Sevelda, P.; Freibauer, C.; Müller, V.; Jänicke, F.; Schmidt, M.; Kölbl, H.; Rody, A.; Kaufmann, M.; Schroth, W.; Brauch, H.; Schwab, M.; Fritz, P.; Weber, K.E.; Feder, I.S.; Hennig, G.; Kronenwett, R.; Gehrmann, M.; Gnant, M.; Investigators, E.P.E.P. EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res., 2011, 17(18), 6012-6020.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-0926] [PMID: 21807638]
[53]
Dubsky, P.; Brase, J.C.; Jakesz, R.; Rudas, M.; Singer, C.F.; Greil, R.; Dietze, O.; Luisser, I.; Klug, E.; Sedivy, R.; Bachner, M.; Mayr, D.; Schmidt, M.; Gehrmann, M.C.; Petry, C.; Weber, K.E.; Fisch, K.; Kronenwett, R.; Gnant, M.; Filipits, M. Austrian Breast and Colorectal Cancer Study Group (ABCSG). The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br. J. Cancer, 2013, 109(12), 2959-2964.
[http://dx.doi.org/10.1038/bjc.2013.671] [PMID: 24157828]
[54]
Martin, M.; Brase, J.C.; Calvo, L.; Krappmann, K.; Ruiz-Borrego, M.; Fisch, K.; Ruiz, A.; Weber, K.E.; Munarriz, B.; Petry, C.; Rodriguez, C.A.; Kronenwett, R.; Crespo, C.; Alba, E.; Carrasco, E.; Casas, M.; Caballero, R.; Rodriguez-Lescure, A. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res., 2014, 16(2), R38.
[http://dx.doi.org/10.1186/bcr3642] [PMID: 24725534]
[55]
Buus, R.; Sestak, I.; Kronenwett, R.; Denkert, C.; Dubsky, P.; Krappmann, K.; Scheer, M.; Petry, C.; Cuzick, J.; Dowsett, M. Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J. Natl. Cancer Inst., 2016, 108(11) djw149
[http://dx.doi.org/10.1093/jnci/djw149] [PMID: 27400969]
[56]
Sotiriou, C.; Wirapati, P.; Loi, S.; Harris, A.; Fox, S.; Smeds, J.; Nordgren, H.; Farmer, P.; Praz, V.; Haibe-Kains, B.; Desmedt, C.; Larsimont, D.; Cardoso, F.; Peterse, H.; Nuyten, D.; Buyse, M.; Van de Vijver, M.J.; Bergh, J.; Piccart, M.; Delorenzi, M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst., 2006, 98(4), 262-272.
[http://dx.doi.org/10.1093/jnci/djj052] [PMID: 16478745]
[57]
Metzger Filho, O.; Ignatiadis, M.; Sotiriou, C. Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis. Crit. Rev. Oncol. Hematol., 2011, 77(1), 20-29.
[http://dx.doi.org/10.1016/j.critrevonc.2010.01.011] [PMID: 20138540]
[58]
Goldhirsch, A.; Ingle, J.N.; Gelber, R.D.; Coates, A.S.; Thürlimann, B.; Senn, H.J. Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol., 2009, 20(8), 1319-1329.
[http://dx.doi.org/10.1093/annonc/mdp322] [PMID: 19535820]
[59]
Liedtke, C.; Hatzis, C.; Symmans, W.F.; Desmedt, C.; Haibe-Kains, B.; Valero, V.; Kuerer, H.; Hortobagyi, G.N.; Piccart-Gebhart, M.; Sotiriou, C.; Pusztai, L. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J. Clin. Oncol., 2009, 27(19), 3185-3191.
[http://dx.doi.org/10.1200/JCO.2008.18.5934] [PMID: 19364972]
[60]
Ignatiadis, M.; Singhal, S.K.; Desmedt, C.; Haibe-Kains, B.; Criscitiello, C.; Andre, F.; Loi, S.; Piccart, M.; Michiels, S.; Sotiriou, C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J. Clin. Oncol., 2012, 30(16), 1996-2004.
[http://dx.doi.org/10.1200/JCO.2011.39.5624] [PMID: 22508827]
[61]
Laios, I.; Carpentier, S.; Veys, I.; Spinette, S.; Salgado, R.; Craciun, L.; Fasolo, V.; Volpe, A.; Girardi, H.; Catteau, A.; Peyro-Saint-Paul, H.; Piccart, M.; Sotiriou, C.; Larsimont, D. PCR genomic grade in breast cancer: a new tool for daily practice. Cancer Res., 2011, 71(Suppl. 24) P1-07-08-P1-07- 08.
[http://dx.doi.org/10.1158/0008-5472.SABCS11-P1-07-08]
[62]
Thürlimann, B.; Keshaviah, A.; Coates, A.S.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R.D.; Rabaglio, M.; Smith, I.; Wardley, A.; Price, K.N.; Goldhirsch, A. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med., 2005, 353(26), 2747-2757.
[http://dx.doi.org/10.1056/NEJMoa052258] [PMID: 16382061]
[63]
Regan, M.M.; Neven, P.; Giobbie-Hurder, A.; Goldhirsch, A.; Ejlertsen, B.; Mauriac, L.; Forbes, J.F.; Smith, I.; Láng, I.; Wardley, A.; Rabaglio, M.; Price, K.N.; Gelber, R.D.; Coates, A.S.; Thürlimann, B. BIG 1-98 Collaborative Group. International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol., 2011, 12(12), 1101-1108.
[http://dx.doi.org/10.1016/S1470-2045(11)70270-4] [PMID: 22018631]
[64]
Ignatiadis, M.; Azim, H.A., Jr; Desmedt, C.; Veys, I.; Larsimont, D.; Salgado, R.; Lyng, M.B.; Viale, G.; Leyland-Jones, B.; Giobbie-Hurder, A.; Kammler, R.; Dell’Orto, P.; Rothé, F.; Laïos, I.; Ditzel, H.J.; Regan, M.M.; Piccart, M.; Michiels, S.; Sotiriou, C. The genomic grade assay compared with Ki67 to determine risk of distant breast cancer recurrence. JAMA Oncol., 2016, 2(2), 217-224.
[http://dx.doi.org/10.1001/jamaoncol.2015.4377] [PMID: 26633571]
[65]
Jerevall, P.L.; Ma, X.J.; Li, H.; Salunga, R.; Kesty, N.C.; Erlander, M.G.; Sgroi, D.C.; Holmlund, B.; Skoog, L.; Fornander, T.; Nordenskjöld, B.; Stål, O. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br. J. Cancer, 2011, 104(11), 1762-1769.
[http://dx.doi.org/10.1038/bjc.2011.145] [PMID: 21559019]
[66]
Ma, X.J.; Salunga, R.; Dahiya, S.; Wang, W.; Carney, E.; Durbecq, V.; Harris, A.; Goss, P.; Sotiriou, C.; Erlander, M.; Sgroi, D. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res., 2008, 14(9), 2601-2608.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-5026] [PMID: 18451222]
[67]
Jankowitz, R.C.; Cooper, K.; Erlander, M.G.; Ma, X.J.; Kesty, N.C.; Li, H.; Chivukula, M.; Brufsky, A. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. Breast Cancer Res., 2011, 13(5), R98.
[http://dx.doi.org/10.1186/bcr3038] [PMID: 21999244]
[68]
Ma, X.J.; Hilsenbeck, S.G.; Wang, W.; Ding, L.; Sgroi, D.C.; Bender, R.A.; Osborne, C.K.; Allred, D.C.; Erlander, M.G. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J. Clin. Oncol., 2006, 24(28), 4611-4619.
[http://dx.doi.org/10.1200/JCO.2006.06.6944] [PMID: 17008703]
[69]
Goetz, M.P.; Suman, V.J.; Ingle, J.N.; Nibbe, A.M.; Visscher, D.W.; Reynolds, C.A.; Lingle, W.L.; Erlander, M.; Ma, X.J.; Sgroi, D.C.; Perez, E.A.; Couch, F.J. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin. Cancer Res., 2006, 12(7 Pt 1), 2080-2087.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-1263] [PMID: 16609019]
[70]
Jerevall, P.L.; Brommesson, S.; Strand, C.; Gruvberger-Saal, S.; Malmström, P.; Nordenskjöld, B.; Wingren, S.; Söderkvist, P.; Fernö, M.; Stål, O. Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res. Treat., 2008, 107(2), 225-234.
[http://dx.doi.org/10.1007/s10549-007-9541-8] [PMID: 17453342]
[71]
Jerevall, P.L.; Jansson, A.; Fornander, T.; Skoog, L.; Nordenskjöld, B.; Stål, O. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Res., 2010, 12(4), R53.
[http://dx.doi.org/10.1186/bcr2612] [PMID: 20649975]

Rights & Permissions Print Cite
Article Metrics
68
6
1
1
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy